ADLM opposes CMS proposal to eliminate board certification for high-complexity laboratory directors
ADLM opposes CMS proposal to eliminate board certification for high-complexity laboratory directors
PR Newswire
WASHINGTON, Oct. 19, 2026
WASHINGTON, Oct. 19, 2026 /PRNewswire/ -- The following statement is attributable to Stanley F. Lo, PhD, DABCC, FADLM, president of the Association for Diagnostics & Laboratory Medicine (ADLM):
"The Association for Diagnostics & Laboratory Medicine strongly opposes a proposed rule from the Centers for Medicare & Medicaid Services (CMS) that would eliminate the requirement for doctoral scientists who direct high-complexity clinical laboratories to hold board certification approved by the Department of Health and Human Services (HHS).
"High-complexity laboratories perform sophisticated testing that physicians depend on every day to diagnose disease and guide treatment for patients. Directors of these laboratories oversee all clinical, scientific, and operational aspects of the laboratory. They must have the scientific and clinical expertise to evaluate test methods, validate and monitor test performance in their patient populations, oversee laboratory personnel, advise physicians on appropriate test ordering and interpretation, and investigate errors. Board certification is a critical independent assessment of the specialized knowledge and competence required to provide today's advanced clinical laboratory testing.
"Under the proposed rule, qualifying doctoral scientists could meet federal requirements through 1 year of experience directing or supervising high-complexity testing or 20 hours of continuing education about laboratory director responsibilities. Neither of these alternative measures is equivalent to the independent assessment of specialized knowledge that board certification provides.
"ADLM supports modernizing CLIA and expanding opportunities for qualified scientists from different educational and professional backgrounds. However, expanding these opportunities need not come at the expense of rigorous standards. Laboratory directors must be able to exercise independent scientific judgment, even when they rely on other qualified professionals for specialized technical expertise.
"CMS should retain the HHS-approved board certification requirement for doctoral scientists directing high-complexity laboratories and reconsider the proposed reductions in experience requirements. Patients deserve high-quality care backed by laboratory directors whose qualifications have been independently demonstrated."
About the Association for Diagnostics & Laboratory Medicine (ADLM)
Dedicated to achieving better health for all through laboratory medicine, ADLM unites more than 70,000 clinical laboratory professionals, physicians, research scientists, and business leaders from 110 countries around the world. Our community is at the forefront of laboratory medicine's diverse subdisciplines, including clinical chemistry, molecular diagnostics, mass spectrometry, clinical microbiology, and data science, and is comprised of individuals holding the spectrum of lab-related professional degrees, certifications, and credentials. Since 1948, ADLM has championed the advancement of laboratory medicine by fostering scientific collaboration, knowledge sharing, and the development of innovative solutions that enhance health outcomes. For more information, visit www.myadlm.org.
Christine DeLong
ADLM
Director, Editorial and Media Relations
(p) 202.835.8722
cdelong@myadlm.org
Bill Malone
ADLM
Senior Director, Strategic Communications
(p) 202.835.8756
bmalone@myadlm.org
SOURCE Association for Diagnostics & Laboratory Medicine (ADLM)
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
Are TIPS ETFs the Best Way to Fight Inflation?
10 Best Blue-Chip Stocks to Buy for the Long Term
This 1-Star Stock Trades at a 94% Premium. Is It Time to Sell?
United States